Microdose Tirzepatide

What Is Microdose Tirzepatide?

Tirzepatide is a peptide that mimics GLP-1 and GIP hormones, which help regulate appetite, blood sugar, and metabolism. While higher doses are often used for weight loss, Pro Health offers a microdose option for a gradual, individualized approach to metabolic wellness. No BMI requirement applies, but provider discretion determines eligibility.

How Does It Work?

Tirzepatide supports natural metabolic signaling and may help:

• Reduce cravings and “food noise”
• Improve portion control and hunger awareness
• Support insulin sensitivity
• Promote steadier energy levels
• Reinforce healthy habits and long-term metabolic health

Many patients report improved control over eating and nutrition choices compared to traditional dieting.

Evidence For Microdose Tirzepatide

Clinical studies show benefits for weight, blood sugar, insulin resistance, and metabolic markers, typically at doses of 5 mg or higher. Research on “microdose” use is still emerging. The 1.25 mg program is a conservative wellness approach based on clinical observation, early real-world experience, and emerging data.

Who May Benefit?

Patients who:

• Struggle with cravings or overeating
• Want support maintaining healthy habits
• Are focused on metabolic wellness
• Prefer a gradual approach before higher doses
• Are interested in broader health optimization

Optional Metabolic & Vascular Wellness Panel

Advanced metabolic and vascular labs are available ($150, fasting required). Results are reviewed with a provider to guide personalized recommendations.

How It’s Given

• Weekly under-the-skin injection
• In-clinic or take-home administration
• With or without food
• Individualized dosing with follow-ups

Possible Side Effects

Mild: nausea, diarrhea, constipation (usually temporary).

Rare risks: pancreatitis, gallbladder disease, and thyroid tumors (seen in animal studies). Support medications may be provided if needed.

Who Should Not Use Tirzepatide

• Personal or family history of medullary
  thyroid cancer
• MEN2 (Multiple Endocrine Neoplasia Type 2)
• Pregnancy or breastfeeding
• Severe allergic reaction to tirzepatide

Always review full medical history with a provider before starting.

1) the compounded tirzepatide drugs are compounded drug products that have not been approved by the FDA; have not been reviewed by the FDA for safety, effectiveness, or quality; and have not been demonstrated to FDA to be safe or effective for their intended use; (2) the processes by which the compounded drugs are manufactured have not been reviewed by the FDA; and (3) FDA-approved products containing tirzepatide are available.